IceCure Sees Over 30% Q1 2026 Revenue Growth for ProSense Cryoablation
IceCure's U.S. sales of ProSense systems and cryoprobes rose more than 30% in Q1 2026 versus Q1 2025 based on preliminary estimates. The company showcased its FDA-cleared ProSense cryoablation at the ASBrS 2026 meeting, where guidelines added cryoablation for low-risk breast cancer.
1. Q1 2026 Commercial Performance
IceCure reported preliminary unaudited data showing U.S. ProSense system and cryoprobe revenue increased over 30% in Q1 2026 compared to Q1 2025, driven by expanding adoption in breast oncology clinics.
2. ASBrS 2026 Exhibition and Symposium
At the American Society of Breast Surgeons 2026 Annual Meeting, IceCure exhibited ProSense and hosted a symposium featuring breast surgeons from Cleveland Clinic, University of Michigan, West Cancer Center, and Brown University sharing real-world cryoablation outcomes.
3. FDA Clearance and Guideline Adoption
ProSense received FDA marketing clearance in October 2025 for low-risk breast cancer, and the ASBrS Resource Guide was updated to recommend cryoablation as a minimally invasive option for select early-stage patients.
4. CEO Outlook and Market Potential
CEO Eyal Shamir emphasized that heightened visibility from the ASBrS event and inclusion in treatment guidelines are expected to accelerate commercial momentum and broader adoption of ProSense cryoablation in the U.S. market.